News | September 08, 2014

Excellent Outcomes at Five Years With SAVI Breast Brachytherapy Treatment for Early-stage Breast Cancer

Long-term results show good local control, low toxicity with strut-based brachytherapy

SAVI Breast Brachytherapy Treatment Early-stage Breast Cancer

September 8, 2014 — Cianna Medical Inc., a women’s health company, announced the release of long-term data supporting the efficacy and safety of breast brachytherapy with the SAVI applicator. Researchers reported five-year results for the first 100 patients treated with strut-based brachytherapy, including favorably low rates of local recurrence and toxicities, as well as excellent cosmetic outcomes. 

SAVI is a strut-based applicator that delivers a form of accelerated partial breast irradiation (APBI) known as a breast brachytherapy, a five-day course of targeted radiation for early-stage breast cancer. The five-year actuarial rate for ipsilateral breast tumor recurrence (IBTR) was 3.3 percent, and good/excellent cosmesis was reported in more than 94 percent of patients, according to the study.

“Five-year results is a significant milestone for any medical technology, and physicians should be confident offering SAVI as a safe, effective treatment for patients with early, lower risk breast cancers,” said radiation oncologist Robert Kuske, M.D., co-principal investigator of the SAVI Collaborative Research Group. “It’s encouraging to have another option to deliver highly targeted, precise radiation, as it enables physicians to treat just the area most at risk for recurrence, while reducing side effects and improving overall quality of life for our patients.”

To date, this is the longest follow-up reported by the SAVI Collaborative Research Group, which was created to study the long-term outcomes of women treated with strut-based brachytherapy. The five-year were presented at the 2014 Breast Cancer Symposium, Sept. 4-6, 2014,

“Based on our study, local control is comparable to published results for whole breast irradiation with similar follow-up, while toxicity rates and cosmetic outcomes are often superior with the strut-based device due to its ability to deliver precisely targeted radiation,” Kuske added. “Better cosmetic outcomes, along with the shortened course of treatment, can lead to higher levels of patient satisfaction, which is an important quality measure in today’s changing healthcare environment.”

Strut-based brachytherapy is used as part of breast conservation therapy (BCT), which consists of a lumpectomy followed by radiation therapy. Whole breast irradiation (WBI) radiates the entire breast, including healthy tissue and underlying structures, while breast brachytherapy delivers targeted radiation to the area immediately surrounding the lumpectomy cavity. The clinical benefits of targeted radiation like brachytherapy include reduced radiation exposure to healthy tissue, better cosmetic results, fewer long-term side effects, and preserving more treatment options in the future in the event of a recurrence or new primary cancer.

Patient eligibility for breast brachytherapy includes lower risk cancers, as well as a number of other factors, including tumor size, age, margin status and lymph node involvement. The strut-based, open architecture design of SAVI allows physicians to sculpt radiation based on patient-specific anatomy, which may increase the number of women eligible for breast brachytherapy.

For more information:

Related Content

Sponsored Content | Videos | Radiation Therapy | January 18, 2019
Join Chris Toth, president of Varian’s Oncology Systems business, for a look at product introductions for 2018 plus
Novel Technique May Significantly Reduce Breast Biopsies
News | Breast Biopsy Systems | January 17, 2019
A novel technique that uses mammography to determine the biological tissue composition of a tumor could help reduce...
Digital Mammography Increases Breast Cancer Detection
News | Mammography | January 16, 2019
The shift from film to digital mammography increased the detection of breast cancer by 14 percent overall in the United...
MIM Software Inc. Receives FDA 510(k) Clearance for Molecular Radiotherapy Dosimetry
Technology | Nuclear Imaging | January 16, 2019
MIM Software Inc. received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for molecular radiotherapy...
Artificial Intelligence Used in Clinical Practice to Measure Breast Density
News | Artificial Intelligence | January 15, 2019
An artificial intelligence (AI) algorithm measures breast density at the level of an experienced mammographer,...
Sponsored Content | Videos | Breast Imaging | January 11, 2019
Supplemental screening with ABUS helps personalize breast care for women with dense breasts and offers advanced...
Electronic Brachytherapy Effective in Long-Term Study of 1,000 Early-Stage Breast Cancers
News | Brachytherapy Systems, Women's Healthcare | January 07, 2019
Breast cancer recurrence rates of patients treated with intraoperative radiation therapy (IORT) using the Xoft Axxent...
Brachytherapy Alone Superior Treatment for Intermediate-Risk Prostate Cancer
News | Brachytherapy Systems | January 04, 2019
Patient-reported outcomes (PROs) indicated a significantly different clinician and patient-reported late toxicity...
Breast Cancer Patients Have Less Heart Damage With Heart Drug and Trastuzumab
News | Cardio-oncology | January 03, 2019
Breast cancer patients who take a heart drug at the same time as trastuzumab have less heart damage, according to a...
RayStation 8B Released With Machine Learning Applications for Treatment Planning
Technology | Treatment Planning | December 27, 2018
RaySearch Laboratories released RayStation 8B, the latest version of the radiation therapy treatment planning system (...